COMPANY

Retension Pharmaceuticals

Keywords: cardiovascular hypertension cardiovascular diseases small molecule Uncontrolled Hypertension SLx-2101 RTN-001

Location: Falls Church, VA · source · Oct 15, 2026

Profile checked Oct 10, 2026

Timeline

Oct 31, 2025 Trial start Phase 2: A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension source ↗
2007-07 Trial start Phase 2: Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension source ↗
2007-06 Trial start Phase 2: Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension source ↗

2027-03 (ESTIMATED) · Phase 2 · A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension · NCT07142356

Estimated primary completion per ClinicalTrials.gov. Dates move.

Record	Title	Phase	Status	Start	Primary completion
NCT07142356	A Study of Modified Release RTN-001 In Patients With Uncontrolled Hypertension	Phase 2	Recruiting	Oct 31, 2025	2027-03 (estimated)
NCT00562549	Safety and Effects of SLx-2101 Taken for up to 14 Days on Blood Pressure in Patients With Hypertension	Phase 2	Completed	2007-07	2007-12 (actual)
NCT00562614	Safety and Effect of Oral Doses of 5mg or 10mg of SLx-2101 for 14 Days in Patients With Hypertension	Phase 2	Completed	2007-06	2007-12 (actual)

Form D raises come from the company’s own SEC filing (last 2 years).

2025-05-06 Raise Private raise (SEC Form D): $12.3M sold of $20.0M offered; issuer “Retension Pharmaceuticals, Inc.”. Verified from the SEC filing. SEC filing ↗